Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter
NEW
Videos and interviews
from the International Atherosclerosis Society (IAS)/R3i Joint Consensus Meeting
SESSION 4 presentations and interviews NOW AVAILABLE...
New Horizons in Residual Vascular Risk:
The Selective Peroxisome Proliferator-Activated Receptor alpha Modulator (SPPARMα) Concept
 
SPPARMα: New horizons for residual cardiovascular risk?
 
In the concluding session, experts debated evidence linking to the final question for the SPPARMα concept:
 
Does treatment with the first novel SPPARMα agent reduce residual cardiovascular risk in high risk patients?
HOT OFF THE PRESS
The International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation announce a Joint Consensus Statement on Selective Peroxisome Proliferator Activated Receptor alpha Modulators (SPPARMα)
Read the article...
R3i editorial
19 July 2019

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
International Expert Consensus on Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMα): New opportunities for targeting modifiable residual cardiovascular riskRead more...

Atherogenic dyslipidaemia has long been recognised as a contributor to modifiable residual cardiovascular risk. To date, however, definitive evidence on how best to target this to reduce residual cardiovascular risk is lacking.
The REDUCE-IT trial, discussed as this month’s Landmark Study, supports the rationale of targeting elevated triglycerides, a key feature of atherogenic dyslipidaemia. The results of this trial, however, are confounded on the one hand by the lipid-modifying effects of the placebo, and on the other hand, by the pleiotropic effects of omega-3 fatty acids beyond triglyceride lowering...
landmark study
19 July 2019

REDUCE-IT: Targeting elevated triglycerides reduces residual cardiovascular risk Read more...

Despite best evidence-based medicine including statins, high-risk patients including those with atherosclerotic cardiovascular disease and/or type 2 diabetes mellitus remain at high residual cardiovascular risk.1 Elevated TG - a surrogate for increased TG-rich lipoproteins and their remnants - may contribute to this modifiable lipid-related residual...
focus on...
19 July 2019

Remnant cholesterol and risk of ischaemic stroke Read more...

High levels of remnant cholesterol, i.e. the cholesterol content of triglyceride-rich remnant lipoproteins, is associated causally with an increased risk of ischaemic heart disease and mortality.1-4 There has, however, been debate as to whether high remnant cholesterol levels are also associated with an increased risk...
recent publication

Remnant lipoproteins contain one-third of total plasma cholesterolRead more...

Studies have shown that calculated remnant cholesterol in triglyceride-rich lipoproteins is causally associated with increased risk of ischaemic heart disease,...
recent publication

Remnant cholesterol and coronary atherosclerotic plaque burdenRead more...

Remnant cholesterol is associated with significant coronary atherosclerotic burden even among patients with well-controlled low-density lipoprotein cholesterol (LDL-C) levels, according...
recent publication

PCSK7: Linking atherogenic dyslipidaemia and inflammation in non-alcoholic fatty liver disease?Read more...

Genetic studies played an integral role in elucidation of the role of PCSK9 (proprotein convertase subtilisin/kexin type 9) in cholesterol...
recent publication

New meta-analysis: triglycerides and cardiovascular risk in type 2 diabetes Read more...

Findings from a systematic review and meta-analysis of 31 prospective studies reaffirmed that elevated triglycerides are associated with increased risk...
recent publication

Residual cardiovascular risk: Dyslipidaemia criteria need to be tighterRead more...

A new review makes the case for stricter control of eligibility criteria, particularly among patients with elevated triglycerides, when testing...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.